BLA 761394 · Daiichi Sankyo INC
Datroway
Datopotamab Deruxtecan-Dlnk · Iv (Infusion)
NovelCDER novel approval, Jan 17, 2025: To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 17, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
48
16 Phase 3, 24 recruiting
FAERS reports
859
553 serious, 173 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 27, 2026.
DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ] . ( 1.2 ) adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.3 ) 1.1 Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. 1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is...
Mechanism: Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Following binding to Trop-2 on cells, including tumor cells, datopotamab deruxtecan-dlnk undergoes internalization and intracellular linker cleavage by lysosomal enzymes. Upon release, the membrane-permeable DXd causes DNA damage and apoptotic cell death. Datopotamab deruxtecan-dlnk had anti-tumor activity in mouse models of lung cancer including EGFR-mutated and breast...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 22, 2026 Supplement 3 · Efficacy · priority review LetterLabel
- Jan 17, 2025 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- DATROWAY · DATOPOTAMAB DERUXTECAN-DLNK 100MG · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Datopotamab Deruxtecan" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06112379 · 1,902 participants · Start Nov 14, 2023 · Primary completion Nov 20, 2028
Drug: Dato-DXd; Durvalumab and 8 more · For: Breast Cancer
Sites: Daphne, Alabama; Prescott, Arizona; Jonesboro, Arkansas · 283 sites in all
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05687266 · 1,350 participants · Start Dec 29, 2022 · Primary completion Nov 1, 2027
Drug: Datopotamab deruxtecan; Durvalumab and 5 more · For: NSCLC
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 254 sites in all
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Pivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05555732 · 1,233 participants · Start Jan 11, 2023 · Primary completion May 11, 2029
Drug: Datopotamab Deruxtecan; Pembrolizumab and 3 more · For: Metastatic Non Small Cell Lung Cancer
Sites: Daphne, Alabama; Chandler, Arizona; Prescott Valley, Arizona · 260 sites in all
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05629585 · 1,174 participants · Start Nov 28, 2022 · Primary completion Sep 1, 2027
Drug: Dato-DXd; Durvalumab and 2 more · For: Breast Cancer
Sites: Gilbert, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 276 sites in all
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07720284 · 915 participants (planned) · Start Jul 16, 2026 · Primary completion Sep 11, 2030
Drug: Dato-DXd; Rilvegostomig and 4 more · For: High-risk Muscle Invasive Urothelial Carcinoma
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; San Francisco, California · 160 sites in all
- First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Pivotal-lookingActive, not recruiting
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
NCT03401385 · 890 participants (planned) · Start Jan 31, 2018 · Primary completion Jan 1, 2028
Drug: Datopotamab Deruxtecan (Dato-DXd); Steroid Containing Mouthwash · For: Hormone Receptor Positive Breast Cancer; Triple Negative Breast Cancer; Non-small Cell Lung Cancer
Sites: Los Angeles, California; Washington D.C., District of Columbia; Atlanta, Georgia · 18 sites in all
- A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06417814 · 768 participants · Start Oct 4, 2024 · Primary completion Jan 11, 2027
Drug: Dato-DXd; Osimertinib and 3 more · For: Metastatic Non-small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Fountain Valley, California; San Diego, California · 211 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression256
- stomatitis146
- off label use122
- death51
- no adverse event46
- nausea40
- fatigue33
- dry eye32
- interstitial lung disease31
- dyspnoea26
- rash24
- pneumonitis23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 321 |
| 2026 | 530 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Dent R, Shao Z, Schmid P, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn MJ, Tanaka K, Paz-Ares L, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
Sands J, Ahn MJ, Lisberg A, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Multicenter Study
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A, Krop IE, Kogawa T, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Multicenter Study
- Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
Gadaleta-Caldarola G, Lanotte L, Infusino S, et al. · Cancer Treat Res Commun 2023 · Meta-Analysis, Review
Sponsor: Daiichi Sankyo
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.